טוען...
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
PURPOSE: Among metastatic breast cancer (MBC) patients, those with a triple-negative breast cancer phenotype (mTNBC) have the worst prognosis, but the benefit of chemotherapy beyond second line on outcome remains uncertain. The purpose of this study was to identify predictive factors of outcome afte...
שמור ב:
| הוצא לאור ב: | Breast |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7873471/ https://ncbi.nlm.nih.gov/pubmed/33561617 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2021.01.006 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|